SCHEDULE 13G/A: T. Rowe Price Cuts Celldex Therapeutics Stake to 3.6%

Sentiment:

Beneficial Ownership Report (Amendment) 14 November 2025 12:19 PM

📋All filings for Celldex Therapeutics, INC

T. Rowe Price Associates, Inc. has reduced its beneficial ownership in Celldex Therapeutics Inc. to 3.6%, as disclosed in an amended Schedule 13G filing.

Worse than expectedThe beneficial ownership percentage of T. Rowe Price Associates, Inc. in Celldex Therapeutics Inc. has decreased to 3.6%.This percentage is below the 5% threshold that typically triggers a Schedule 13G filing, indicating a reduction in their stake from a previous position that was 5% or higher.

Summary

T. Rowe Price Associates, Inc. filed an Amendment No. 1 to Schedule 13G regarding its ownership in Celldex Therapeutics Inc.
The filing indicates T. Rowe Price Associates, Inc. now beneficially owns 2,382,701 shares of Celldex Therapeutics Inc. common stock.
This represents 3.6% of the class of securities.
T. Rowe Price Associates, Inc. holds sole voting power over 2,342,174 shares and sole dispositive power over 2,382,518 shares.
The event date requiring this statement was September 30, 2025.
The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 4

Explanation: The filing indicates a reduction in T. Rowe Price Associates, Inc.'s stake in Celldex Therapeutics Inc. to below the 5% threshold, which can be interpreted as a negative signal from a major institutional investor.

Negatives

T. Rowe Price Associates, Inc. has reduced its beneficial ownership in Celldex Therapeutics Inc. to 3.6%, which is below the 5% threshold that typically triggers a Schedule 13G filing, indicating a significant reduction from a previous stake.

Future Outlook

Industry Context

Stakeholder Impact

Shareholders: May view the reduction in institutional ownership as a negative signal, potentially impacting investor confidence and stock price.

Key Dates

Date	Description
09/30/2025	Date of event which requires filing of this statement
11/14/2025	Signature date of the filing

Recommendation

hold

While a significant institutional investor has reduced its stake below the 5% threshold, it still retains a notable 3.6% ownership. This suggests a re-evaluation or reallocation rather than a complete divestment, warranting a 'hold' recommendation with close monitoring for further developments or explanations from the company.

Keywords

Celldex Therapeutics, T. Rowe Price, Schedule 13G, beneficial ownership, institutional investor, common stock, equity stake, investment management

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.